Blastic natural killer cell lymphoma/leukemia (CD56‐positive blastic tumor)

Abstract

These findings suggested that BNKL is a heterogeneous disease and contains at least two subtypes. Although further investigations are needed to settle a marker for distinction, the presence of cutaneous involvement is a useful prognostic factor.